Evidence map›Paper›PMID 25203718›Full record

Trial reportHepatology (Baltimore, Md.)2015

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

Eric G Meissner, Yu-Jin Lee, Anu Osinusi, Zayani Sims, Jing Qin, Dan Sturdevant, John McHutchison, Mani Subramanian, Maureen Sampson, Susanna Naggie and 4 more

Open access · greenAbstract readClinical Trial, Phase II
In one paragraph

Trial report in Hepatology (Baltimore, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Eric G MeissnerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Yu-Jin Lee
Anu Osinusi
Zayani Sims
Jing Qin
Dan Sturdevant
John McHutchison
Mani Subramanian
Maureen Sampson
Susanna Naggie
Keyur Patel
Alan T Remaley
Henry Masur
Shyam Kottilil
National Institutes of Health · USNational Institutes of Health Clinical Center · USNational Heart Lung and Blood Institute · USNational Institute of Allergy and Infectious Diseases · USUniversity of Maryland, Baltimore · USClinical Research Institute · USDuke University · US

Funding

Therapeutic Strategies for the Management of HCV/HIV co- infectionZIAAI000390 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FAUCI, ANTHONY S. · 2009 to 2014
$4.2M
DC Partnership for HIV/AIDS Progress (DC PFAP)ZIACL009010 · CLC · CLINICAL CENTER · PI MASUR, HENRY · 2010 to 2025
$0k
Analysis of Stored Samples Collected Using Previously Expired ProtocolsZIACL009021 · CLC · CLINICAL CENTER · PI MASUR, HENRY · 2015 to 2024
$0k
Development Of New Assays For Lipoprotein TestingZIACL010303 · CLC · CLINICAL CENTER · PI REMALEY, ALAN THOMAS · 2009 to 2017
$0k
Intramural NIH HHS ZIA AI000390
6 · The paper itself

Abstract

unlabelledHepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to disease progression and influences response to therapy. To further understand the impact of HCV infection on host metabolism, we examined changes in serum lipid profiles and intrahepatic expression of lipid-related genes during interferon (IFN)-free treatment of chronic HCV, genotype 1 infection with sofosbuvir and ribavirin (RBV), and explored associations with treatment outcome. Serum lipids (total cholesterol, low-density lipoprotein [LDL], high-density lipoprotein [HDL], and triglycerides [TGs]) and hemoglobin A1C (HbA1C) were measured during treatment, while gene expression of lipid-related genes was assessed using paired pre- and end-of-treatment (EOT) liver biopsies from 8 patients (n=7 sustained virologic response [SVR]; n=1 relapse) and unpaired EOT liver biopsies from 25 patients (n=17 SVR; n=8 relapse). Serum LDL concentration and particle size increased early in therapy, whereas TG concentration and very-low-density lipoprotein particle size decreased concomitantly, irrespective of treatment outcome. Whereas LDL increased in patients regardless of treatment outcome, average LDL concentration was lower at baseline and post-treatment in patients who relapsed. Analysis of paired liver biopsies revealed altered expression of genes associated with lipid transport, assembly, and signaling. In unpaired EOT liver biopsies, intrahepatic expression of fatty acid metabolism and lipid transport genes was lower in patients who experienced treatment relapse.

conclusionClearance of HCV using an IFN-free antiviral regimen results in rapid changes in peripheral and intrahepatic metabolic pathways, implicating a direct effect of HCV replication on lipid homeostasis.

Indexed as

Antiviral AgentsFemaleGenotypeHepacivirusHepatitis C, ChronicHumansLipid MetabolismLipoproteins, LDLMaleMiddle AgedRibavirinSofosbuvirUridine MonophosphateVirus ReplicationAntiviral AgentsLipoproteins, LDLRibavirinSofosbuvirUridine Monophosphate

Identifiers

PMID25203718
PMCPMC4340816
OpenAlexW2022396880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.